GLP1R and diabetes mellitus: Villumsen et al. conducted a nationwide Danish registry study involving 3751 patients with IBD and type 2 diabetes mellitus (T2DM), comparing those receiving GLP-1-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) to those on other antidiabetic medications (n = 2769) [28].